274 related articles for article (PubMed ID: 35691098)
1. The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma.
Wusiman D; Guo L; Huang Z; Li Z; Liu S; Ying J; Li W; An C
Pathol Res Pract; 2022 Aug; 236():153934. PubMed ID: 35691098
[TBL] [Abstract][Full Text] [Related]
2. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
4. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
Hirshoren N; Al-Kharouf I; Weinberger JM; Eliashar R; Popovtzer A; Knaanie A; Fellig Y; Neuman T; Meir K; Maly A; Vainer GW
Oncology; 2021; 99(7):464-470. PubMed ID: 33789303
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in fine-needle aspiration cell blocks of head and neck squamous-cell carcinoma and its cytohistological concordance.
Lou SSK; Ruff H; MacDonald S; Smith SM; Cheung CC
Diagn Cytopathol; 2024 Mar; 52(3):163-170. PubMed ID: 38095142
[TBL] [Abstract][Full Text] [Related]
6. Comparison of PD-L1 IHC 22C3 PharmDx Combined Positive Score (CPS) in Primary Versus Metastatic Nodal Squamous Cell Carcinomas of the Head and Neck: Is There a Significant Difference?
Surucu A; Hou T; Kuhar M; Durm G; Mesa H
Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):550-554. PubMed ID: 37358840
[TBL] [Abstract][Full Text] [Related]
7. Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry.
Mishra PS; Sidhu A; Dwivedi G; Mulajker DS; Awasthi S
Indian J Cancer; 2022; 59(4):474-479. PubMed ID: 33753620
[TBL] [Abstract][Full Text] [Related]
8. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
Vainer G; Huang L; Emancipator K; Nuti S
PLoS One; 2023; 18(6):e0285764. PubMed ID: 37267266
[TBL] [Abstract][Full Text] [Related]
9. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
de Ruiter EJ; Mulder FJ; Koomen BM; Speel EJ; van den Hout MFCM; de Roest RH; Bloemena E; Devriese LA; Willems SM
Mod Pathol; 2021 Jun; 34(6):1125-1132. PubMed ID: 32759978
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of CD103
Smith JD; Bellile EL; Ellsperman SE; Heft-Neal ME; Mann JE; Birkeland AC; Hoesli RC; Swiecicki PL; Worden FP; Schonewolf C; Shah JL; Mierzwa ML; Rosko AJ; Stucken CL; Chinn SB; Shuman AG; Casper KA; Malloy KM; Prince MEP; Wolf GT; Thomas DG; McHugh JB; Chad Brenner J; Spector ME
Oral Oncol; 2022 Dec; 135():106226. PubMed ID: 36323071
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical study of Programmed Cell Death Ligand 1 (PDL1) expression by combined positive score using 22C3 clone in head and neck squamous cell carcinomas, its correlation with clinicopathological features and outcome.
Gangadhar P; Ilanthodi S; Shetty R; Shenoy KK; Philipose TR
J Oral Maxillofac Pathol; 2024; 28(1):29-36. PubMed ID: 38800420
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
Burtness B; Rischin D; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Brana I; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesia R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Ge J; Swaby RF; Gumuscu B; Harrington K
J Clin Oncol; 2022 Jul; 40(21):2321-2332. PubMed ID: 35333599
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
15. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
[TBL] [Abstract][Full Text] [Related]
16. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
[TBL] [Abstract][Full Text] [Related]
17. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of PD-L1 expression in head and neck squamous cell carcinoma: An institutional experience from India.
Kala PS; Thapliyal N; Pant B; Sharma N; Pandey HS
Pathol Res Pract; 2024 Feb; 254():155133. PubMed ID: 38306860
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck.
Park BJ; Mattox AK; Clayburgh D; Patel M; Bell RB; Yueh B; Leidner R; Xiao H; Couey M; Li S; Qin T; Sartor MA; Cairns B; MacDonough T; Halliwill K; Deschler D; Lin DT; Faquin WC; Sadow PM; Pai SI
Oral Oncol; 2022 Dec; 135():106183. PubMed ID: 36215771
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in head and neck squamous cell carcinoma and its clinical significance: A prospective observational study from a tertiary care centre.
Kilaru S; Panda SS; Moharana L; Mohapatra D; Mohapatra SSG; Panda A; Kolluri S; Devaraj S; Kabi A; Das B; Biswas G
J Cancer Res Ther; 2024 Jan; 20(1):46-51. PubMed ID: 38554297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
